Accepted for publication on May 18, 2026 Abstract Despite growing evidence supporting the efficacy of azathioprine, methotrexate, and cyclosporine in halting vitiligo progression and promoting repigmentation, these agents remain underutilized in r...
Our Publications
The Vitiligo Research Foundation is proud to contribute to advancing vitiligo understanding and treatment through a wide range of co-authored publications. From groundbreaking therapeutic approaches and patient-reported outcomes to global awareness initiatives like World Vitiligo Day, our work bridges research, patient advocacy, and innovative AI-tools. Explore the full list below to see how we’re shaping the future of vitiligo care and education.
- 2026
- 2025
Vitiligo is a disease that causes white patches to appear on the skin. The study described here analyzed whether vitiligo is more difficult for people with darker skin. To answer this question, the authors used data from a large patient survey cal...
- 2025
This paper builds on earlier research on the Vitiligo Patient Journey by providing a profile of a typical individual navigating the care landscape—from awareness to diagnosis, treatment, or coping. Vitiligo affects roughly 1% of the US population,...
- 2025
This paper presents an overview of vitiligo as an autoimmune disorder with a complex genetic background, highlighting how artificial intelligence (AI) is transforming its diagnosis and treatment. Researchers have identified around 50 genes linked ...
- 2025
This paper presents a transformative framework for vitiligo care, addressing its psychological, physiological, and social impacts. It highlights the high prevalence of psychiatric comorbidities, autoimmune links, and social stigma while emphasizin...
- 2025
Dermatology encompasses over 3,000 diseases, yet comprehensive data on patient experiences from onset to treatment remain limited. Traditional patient journey maps often oversimplify chronic conditions like vitiligo, failing to capture their non-l...
- 2025
World Vitiligo Day (WVD) is a transformative model of medical advocacy, demonstrating how patient-led initiatives can shift public perception, empower patients, influence legal frameworks, and attract pharmaceutical investment. The WVD Presidentia...
- 2024
We would like to share our experience with the World Vitiligo Day (WVD) annual campaign headquarters in Mexico and highlight its impact both online and offline, offering it as a potential model for future events. The 12th edition of WVD, hosted in...
- 2023
In this population-based qualitative study, 3541 patients with vitiligo across 17 countries reported substantial burden on quality of life, emotional well-being, daily life, and psychosocial health, with greater burden noted among patients with mo...
- 2023
The Vitiligo and Life Impact Among International Communities (VALIANT) study is the first global survey to explore the natural history and management of vitiligo from the perspectives of patients and healthcare professionals (HCPs).
- 2022
This qualitative study found that, globally, patients with vitiligo reported being substantially affected in their emotional well-being, daily lives, and psychosocial health; the burden was typically greatest among patients with more than 5% affec...
- 2022
Methotrexate has shown potential as a treatment for advanced vitiligo, particularly in cases of rapidly progressing or unstable disease. It works by interfering with DNA synthesis and inducing apoptosis in active CD4+ T cells, while also reducing ...
- 2021
The Vitiligo and Life Impact Among International Communities (VALIANT) study is the first global survey to explore the natural history and management of vitiligo from the perspectives of 3541 patients and 1203 healthcare professionals. Patients wi...
- 2020
This review aims at a comprehensively describing the treatments available and the emerging treatment aspects and the scope for future developments.Areas covered: This study comprehensively summarizes the current concepts in the pathogenesis of vit...
- 2019
Vitiligo is a relatively common disorder characterized by areas of depigmented skin. It may be associated with social stigma and adversely affects the quality of life. Although many treatment options are available, none is curable. The search cont...
- 2019
This traditional annual meeting represents the most important interactive event involving experts in Dermatological and Pediatric Sciences in the Mediterranean Region under the Presidency of Professors Fabio Arcangeli , Patrizio Mulas and Mirella ...
- 2019
World Vitiligo Day has once again swept the globe in a day of celebration and action in support of the estimated 100 million vitiligo sufferers worldwide. [...] VR Foundation strives on a daily basis for recognition of vitiligo by global leaders, ...
- 2019
This Letter to Editor seeks to update doctors, healthcare professionals, insurers and payers, health ministries, philanthropic institutions, vitiligo patients and their families on the World Vitiligo Day campaign.
- 2019
The XIX Congress was an enormous scientific and social success with an outstanding participation of speakers, delegates, and exhibitors. Among the speakers Prof. Diamond Thaçi from Germany brilliantly shared with the audience the role of dupilumab...
- 2018
Despite the continuous introduction of innovative therapies for vitiligo, today none of them provide constant and excellent results in term of repigmentation. The authors report their experience in treating a localised form of vitiligo with a new ...
- 2018
The aim of the study is to contribute to the scant research on the patient-reported outcomes in vitiligo, and to examine the presence of associations between various inputs for possible use in clinical practice. The study was designed as a web-bas...
- 2018
Vitiligo is quite a common hypopigmentary disorder, which may affect both children and adults with important psychological effects due to the well-known leopard skin-like appearance. The authors summarize in the present study the published evidenc...
- 2018
Vitiligo is a common disease of unknown cause that produces disfiguring white patches of depigmentation that can be treated using various new and experimental therapies, such as narrow-band ultraviolet B (NB-UVB) microphototherapy, NB-UVB excimer ...
- 2017
Senescence grey hair equally affects women and man. To-date, the only treatment available for grey hair is application of temporary hair dye which needs to be applied frequently and often adversely effect the hair, hair follicle, and scalp. Numero...
- 2017
Simvastatin inhibits interferon-γ signaling by blocking activation of STAT and prevented and reversed disease in our mouse model. We conducted a small, randomized, double-blind, placebo-controlled, phase II clinical trial to test simvastatin as a ...
- 2016
In previous linkage and genome-wide association studies (GWAS1, GWAS2), we identified 27 vitiligo susceptibility loci in patients of European (EUR) ancestry. We carried out a third GWAS (GWAS3) in EUR subjects, with augmented GWAS1 and GWAS2 contr...
- 2016
We investigated a worldwide prevalence of vitiligo with population- or community-based and hospital-based data. To our knowledge, this is the first meta-analysis of 103 studies examining the prevalence of vitiligo. The results of this study showed...
- 2016
A collective monography. 352 pages. September 2016. ISBN 978-601-80599-3-3
- 2016
This study is designed to check the glabrous lesional skin for the presence of stem cells as source of melanocytes for repigmentation. Our results demonstrate that NGFRp75-positive stem cells are present in the glabrous lesional skin of vitiligo p...
- 2016
For decades, research in autoimmunity has focused primarily on immune contributions to disease. Yet recent studies report elevated levels of reactive oxygen species (ROS) and abnormal activation of the unfolded protein response (UPR) in cells targ...
- 2015
We sought to identify new treatments for vitiligo, and first considered repurposed medications because of the availability of safety data and expedited regulatory approval. We previously reported that the IFN-γ-induced chemokine CXCL10 is expresse...
- 2015
Although non-segmental vitiligo (NSV) results from the autoimmune destruction of melanocytes, the detailed immune mechanisms have not yet been fully elucidated. Th17 cells have been identified to be implicated in human autoimmune diseases. In this...
- 2015
We study the efficiency of acid peptidoglycan ofplant origin with immunomodulatory activity in therapy of vitiligo. Twenty-five patients with active vitiligo received a course of treatment (6 injections). The activity of vitiligo was evaluated aft...
- 2014
Georgian Med News. 2014 Oct;(235): 45-8
- 2014
ISBN 978-953-7959-26-5 HDVD HLZ-a
- 2014
J Dermatolog Treat. 2014 Nov 27:1-21
- 2014
Pigmentary Disorders 1:133. doi: 10.4172/jpd.1000133
- 2014
J Dermatolog Treat. 2014 Aug 26:1-7. PMID: 25102894
- 2014
Dermatol Ther. 2014 Feb 18. doi: 10.1111/dth.12121. PMID: 24548590
- 2014
Sci Transl Med. 2014 Feb 12;6(223):223ra23. [PMID: 24523323]
- 2014
Exp Dermatol. 2014 Feb;23(2):140-2 [PMID: 24401108]
- 2014
Pigmentary Disorders 2014, 1:5
- 2014
Pigmentary Disorders 2014, 1:1
- 2013
J Dermatol Sci. 2013 Sep; 71(3):212-4
- 2013
Pigment Cell Melanoma Res. 2013 May; 26(3):418-21
- 2013
Russ J Skin Sex Transm Dis. 2013; (2): 35-39
- 2012
(2012) Dermatologic Therapy, 25: S1–S9
- 2012
(2012) Dermatologic Therapy, 25: S10–S16
- 2012
(2012) Dermatologic Therapy, 25: S17–S27
- 2012
(2012) Dermatologic Therapy, 25: S28–S31
- 2012
(2012) Dermatologic Therapy, 25: S32–S40
- 2012
(2012) Dermatologic Therapy, 25: S41–S43
- 2012
Dermatologic Therapy, 25: S44–S56. 2012
- 2012
- 2012
Pigment Cell Melanoma Res. 2012; 25(5): 602-611
- 2012
Russ J Skin Sex Transm Dis. 2012, (3): 37-41
- 2012
Russ J Skin Sex Transm Dis. 2012; (1): 40-42
- 2012
Russ J Skin Sex Transm Dis. 2012; (1): 65
- 2012
Russ J Skin Sex Transm Dis. 2012; (5): 56-59
- 2011
Treat Strategies (Dermatol). 2011; 1(1): 82-86
- 2011
World Health Academy Publication House (Zurich, CH), 2011
- 2011
Russ J Skin Sex Transm Dis. 2011; (1): 68-70
- 2010
Russ J Skin Sex Transm Dis. 2010; (2): 36-39
- 2009
Russ J Skin Sex Transm Dis. 2009; (2): 27-31
FAQOther Questions
- Who is prone to vitiligo?
Vitiligo can affect anyone, regardless of gender, age, or race. Vitiligo prevalence is between 0.76% and 1.11% of the U.S. population, including around 40% of those with the con...
- Diabetes and Vitiligo: Is There a Connection?
Yes, there appears to be a real connection between vitiligo and diabetes, especially type 1 diabetes. A recent study using UK Biobank data also found an association with type 2 ...
- What are risks of oral and topical corticosteroids?
Corticosteroid drugs (like hydrocortisone, and others) are often used for treating vitiligo. By mimicing the effects of hormones your body produces naturally in your adrenal gla...
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.
Copyright (C) Bodolóczki JúliaBy taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.